-
Something wrong with this record ?
Effect of co-milling on dissolution rate of poorly soluble drugs
M. Slámová, K. Prausová, J. Epikaridisová, J. Brokešová, M. Kuentz, J. Patera, P. Zámostný
Language English Country Netherlands
Document type Journal Article
- MeSH
- Indomethacin MeSH
- Pharmaceutical Preparations * MeSH
- Povidone * MeSH
- Drug Compounding MeSH
- Solubility MeSH
- Particle Size MeSH
- Publication type
- Journal Article MeSH
Co-milling of a drug with a co-former is an efficient technique to improve the solubility of drugs. Besides the particle size reduction, the co-milling process induces a structural disorder and the creation of amorphous regions. The extent of drug solubility enhancement is dependent on the proper choice of co-milling co-former. The aim of this work was to compare the effects of different co-formers (meglumine and polyvinylpyrrolidone) on the dissolution rates of glass forming (indomethacin) and non-glass forming (mefenamic acid) model drugs. A positive impact of the co-milling on the dissolution behavior was observed in all co-milled mixtures, even if no substantial amorphization was observed. While meglumine exhibited pronounced effects on the dissolution rate of both drugs, the slightest enhancement was observed in mixtures with polyvinylpyrrolidone. The evaluation of specific release rate revealed the surface activation of drug particle is responsible for improving the dissolution rate of both drug types, but for the glass former, this surface activation could be persistent while maintaining a high dissolution rate even until a high fraction of drug is released. Our results, therefore, indicate that adequate co-former choice and consideration of drug glass forming ability are important for a successful co-milling approach to poorly water-soluble drugs.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019043
- 003
- CZ-PrNML
- 005
- 20210830100620.0
- 007
- ta
- 008
- 210728s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijpharm.2021.120312 $2 doi
- 035 __
- $a (PubMed)33540023
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Slámová, Michaela $u Department of Organic Technology, UCT Prague, Technická 5, 166 28 Prague 6, Dejvice, Czech Republic. Electronic address: slamovam@vscht.cz
- 245 10
- $a Effect of co-milling on dissolution rate of poorly soluble drugs / $c M. Slámová, K. Prausová, J. Epikaridisová, J. Brokešová, M. Kuentz, J. Patera, P. Zámostný
- 520 9_
- $a Co-milling of a drug with a co-former is an efficient technique to improve the solubility of drugs. Besides the particle size reduction, the co-milling process induces a structural disorder and the creation of amorphous regions. The extent of drug solubility enhancement is dependent on the proper choice of co-milling co-former. The aim of this work was to compare the effects of different co-formers (meglumine and polyvinylpyrrolidone) on the dissolution rates of glass forming (indomethacin) and non-glass forming (mefenamic acid) model drugs. A positive impact of the co-milling on the dissolution behavior was observed in all co-milled mixtures, even if no substantial amorphization was observed. While meglumine exhibited pronounced effects on the dissolution rate of both drugs, the slightest enhancement was observed in mixtures with polyvinylpyrrolidone. The evaluation of specific release rate revealed the surface activation of drug particle is responsible for improving the dissolution rate of both drug types, but for the glass former, this surface activation could be persistent while maintaining a high dissolution rate even until a high fraction of drug is released. Our results, therefore, indicate that adequate co-former choice and consideration of drug glass forming ability are important for a successful co-milling approach to poorly water-soluble drugs.
- 650 _2
- $a příprava léků $7 D004339
- 650 _2
- $a indomethacin $7 D007213
- 650 _2
- $a velikost částic $7 D010316
- 650 12
- $a léčivé přípravky $7 D004364
- 650 12
- $a povidon $7 D011205
- 650 _2
- $a rozpustnost $7 D012995
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Prausová, Kateřina $u Department of Organic Technology, UCT Prague, Technická 5, 166 28 Prague 6, Dejvice, Czech Republic
- 700 1_
- $a Epikaridisová, Julie $u Department of Organic Technology, UCT Prague, Technická 5, 166 28 Prague 6, Dejvice, Czech Republic
- 700 1_
- $a Brokešová, Jana $u Faculty of Pharmacy, Department of Pharmaceutical Technology, Charles University, Ak. Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
- 700 1_
- $a Kuentz, Martin $u University of Applied Sciences and Arts Northwestern Switzerland, Institute of Pharmaceutical Technology, Gründenstr. 40, CH-4132 Muttenz, Switzerland
- 700 1_
- $a Patera, Jan $u Department of Organic Technology, UCT Prague, Technická 5, 166 28 Prague 6, Dejvice, Czech Republic
- 700 1_
- $a Zámostný, Petr $u Department of Organic Technology, UCT Prague, Technická 5, 166 28 Prague 6, Dejvice, Czech Republic
- 773 0_
- $w MED00002359 $t International journal of pharmaceutics $x 1873-3476 $g Roč. 597, č. - (2021), s. 120312
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33540023 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830100620 $b ABA008
- 999 __
- $a ok $b bmc $g 1689968 $s 1139489
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 597 $c - $d 120312 $e 20210201 $i 1873-3476 $m International journal of pharmaceutics $n Int. j. pharm. $x MED00002359
- LZP __
- $a Pubmed-20210728